Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04853316 · ClinicalTrials.gov registry record
Asymptomatic SARS-CoV-2 Detection in Children
A clinical trial of COVID-19 and SARS-CoV-2, sponsored by University of Calgary.
- Completed
- Registry status
- 372
- Enrollment target
- 5
- Study locations
NCT04853316: Completed study of COVID-19 and SARS-CoV-2, sponsored by University of Calgary.
NCT04853316 is a study of COVID-19 and SARS-CoV-2 that has completed, run by University of Calgary. The registered enrollment target is 372 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04853316, a study of COVID-19 and SARS-CoV-2, has completed, sponsored by University of Calgary.
- COMPLETED
- Registry status
- 372 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of this study is quantify the transmission risk posted by SARS-CoV-2 in pre/asymptomatic infected children in order to inform the public health response to the COVID-19 pandemic.
Primary Outcome
The clinical secondary attack rate (SAR) for households of participating children, which will be compared to generate the relative SAR for households of children with varying case and symptom statuses.
Conditions Studied
Study Locations (5)
Alabama
- Children's of Alabama - Birmingham
California
- University of California, San Diego - Rady Children's Hospital - San Diego
Massachusetts
- Boston Children's Hospital - Boston
Texas
- Children's Medical Center of Dallas - UT Southwestern - Dallas
Alberta
- Alberta Children's Hospital - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2021-01-31 |
| Est. Completion | 2022-08-22 |
What the finished NCT04853316 record still lists
NCT04853316 is an observational study that tracks outcomes without assigning an intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.
NCT04853316 lists 5 locations in 5 states (Alabama, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT04853316 about?
NCT04853316 is a clinical study titled "Asymptomatic SARS-CoV-2 Detection in Children". The primary objective of this study is quantify the transmission risk posted by SARS-CoV-2 in pre/asymptomatic infected children in order to inform the public health response to the COVID-19 pandemic.
What is the current status of trial NCT04853316?
This trial is currently completed. The enrollment target is 372 participants. The study started on 2021-01-31. Estimated completion is 2022-08-22.
What conditions does trial NCT04853316 study?
This clinical trial studies the following conditions: COVID-19, SARS-CoV-2.
Who is sponsoring clinical trial NCT04853316?
This trial is sponsored by University of Calgary, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04853316 being conducted?
This trial has 5 study locations across Alabama, California, Massachusetts, Texas, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04853316's enrollment target sits among peer trials
372 128th of 298 higher than 171 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI